Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 300-305

  Taglieri, Nevio ^a   Fernandez Berges, Daniel J ^b   Koenig, Wolfgang ^c   Consuegra Sanchez, Luciano ^d   Fernandez, José Maria Cruz ^e   Robles, Nicolas Roberto ^f   Sánchez, Pedro Luis ^g   Beiras, Alfonso Castro ^h   Orbe, Pedro Maria Montes ⁱ   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL DON BENITO VILLANUEVA   (Spain)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Hospital Universitario Del Rosell   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f UNIVERSITY OF SALAMANCA   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL JUAN CANALEJO   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

Author keywords

Acute coronary syndrome; Cystatin C; Renal dysfunction; Risk stratification

Indexed keywords

CREATININE; CYSTATIN C;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SOUTHERN EUROPE; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

EID: 77049086547     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.022     Document Type: Article

References (38)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 November (17) (2007) 2038-2047
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 February (2 Suppl. 1) (2002) S1-266
3. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 October (17) (2003) 2154-2169
4. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 September (13) (2004) 1296-1305
5. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 September (13) (2004) 1285-1295
6. Ninomiya T., Kiyohara Y., Tokuda Y., et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 118 December (25) (2008) 2694-2701
7. Dharnidharka V.R., Kwon C., and Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40 2 (2002) 221-226
8. Grubb A., Nyman U., Bjork J., et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51 8 (2005) 1420-1431
9. Grubb A., Bjork J., Lindstrom V., Sterner G., Bondesson P., and Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 65 2 (2005) 153-162
10. Ix J.H., Shlipak M.G., Chertow G.M., and Whooley M.A. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115 January (2) (2007) 173-179
11. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 May (20) (2005) 2049-2060
12. Shlipak M.G., Katz R., Fried L.F., et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45 January (2) (2005) 268-271
13. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 17 1 (2006) 254-261
14. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 October (19) (2003) 2345-2353
15. Yan A.T., Yan R.T., Tan M., et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 28 9 (2007) 1072-1078
16. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., and Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110 October (16) (2004) 2342-2348
17. Marrugat J., Elosua R., Aldasoro E., et al. Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998. Eur J Epidemiol 19 9 (2004) 831-839
18. Kaski J.C., Cruz-Fernandez J.M., Fernandez-Berges D., et al. Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (systemic inflammation evaluation in patients with non-ST segment elevation acute coronary syndromes). Rev Esp Cardiol 56 4 (2003) 389-395
19. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 October (7) (2002) 1366-1374
20. Bertrand M.E., Simoons M.L., Fox K.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 23 (2002) 1809-1840
21. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 130 October (6) (1999) 461-470
22. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 July (2) (2003) 137-147
23. Ix J.H., Shlipak M.G., Liu H.H., Schiller N.B., and Whooley M.A. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 14 12 (2003) 3233-3238
24. Keller T., Messow C.M., Lubos E., et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 30 3 (2009) 314-320
25. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51 2 (2005) 321-327
26. Windhausen F., Hirsch A., Fischer J., et al. Cystatin C for Enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem (2009) 9
27. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 August (7) (2000) 835-842
28. Shlipak M.G., Katz R., Sarnak M.J., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 August (4) (2006) 237-246
29. Muntner P., Hamm L.L., Kusek J.W., Chen J., Whelton P.K., and He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140 January (1) (2004) 9-17
30. Shlipak M.G., Katz R., Cushman M., et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 118 12 (2005) 1416
31. Eriksson P., Deguchi H., Samnegard A., et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 24 3 (2004) 551-557
32. Sukhova G.K., Shi G.P., Simon D.I., Chapman H.A., and Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102 August (3) (1998) 576-583
33. Liu J., Sukhova G.K., Sun J.S., Xu W.H., Libby P., and Shi G.P. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24 8 (2004) 1359-1366
34. Shi G.P., Sukhova G.K., Grubb A., et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104 9 (1999) 1191-1197
35. Bengtsson E., To F., Hakansson K., et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25 10 (2005) 2151-2156
36. Oorni K., Sneck M., Bromme D., et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 279 August (33) (2004) 34776-34784
37. Lutgens E., Lutgens S.P., Faber B.C., et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 113 January (1) (2006) 98-107
38. Rodgers K.J., Watkins D.J., Miller A.L., et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 26 4 (2006) 851-856